Aby J. Mathew Sells 547 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 547 shares of BioLife Solutions stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $23.15, for a total transaction of $12,663.05. Following the completion of the sale, the executive vice president now owns 317,169 shares of the company’s stock, valued at $7,342,462.35. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

BioLife Solutions Stock Up 2.9 %

Shares of BioLife Solutions stock traded up $0.67 on Friday, reaching $24.07. 216,491 shares of the company were exchanged, compared to its average volume of 367,540. The stock’s 50 day moving average price is $24.07 and its 200-day moving average price is $22.10. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.86 and a quick ratio of 1.81. BioLife Solutions, Inc. has a 1-year low of $9.92 and a 1-year high of $26.73. The company has a market cap of $1.11 billion, a P/E ratio of -14.24 and a beta of 1.88.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.08. BioLife Solutions had a negative net margin of 59.88% and a negative return on equity of 10.75%. The company had revenue of $28.33 million during the quarter, compared to analysts’ expectations of $23.80 million. As a group, equities analysts forecast that BioLife Solutions, Inc. will post -0.36 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on BLFS shares. Northland Securities lifted their price objective on BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. TD Cowen boosted their price target on shares of BioLife Solutions from $20.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, July 17th. Craig Hallum raised their price objective on shares of BioLife Solutions from $23.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, HC Wainwright assumed coverage on shares of BioLife Solutions in a research note on Monday, September 30th. They set a “buy” rating and a $29.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, BioLife Solutions has a consensus rating of “Moderate Buy” and a consensus target price of $26.67.

Hedge Funds Weigh In On BioLife Solutions

Several large investors have recently bought and sold shares of BLFS. Summit Global Investments acquired a new position in shares of BioLife Solutions during the 3rd quarter worth about $228,000. Principal Financial Group Inc. lifted its stake in BioLife Solutions by 4.7% during the third quarter. Principal Financial Group Inc. now owns 190,715 shares of the medical equipment provider’s stock worth $4,776,000 after purchasing an additional 8,580 shares during the last quarter. Harbor Capital Advisors Inc. boosted its holdings in BioLife Solutions by 31.0% in the third quarter. Harbor Capital Advisors Inc. now owns 52,449 shares of the medical equipment provider’s stock valued at $1,313,000 after purchasing an additional 12,421 shares in the last quarter. Raymond James & Associates increased its stake in BioLife Solutions by 4.3% in the third quarter. Raymond James & Associates now owns 139,997 shares of the medical equipment provider’s stock valued at $3,506,000 after purchasing an additional 5,803 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in BioLife Solutions by 29.4% during the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 748 shares in the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.